Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Working Capital Changes (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Working Capital Changes for 13 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 132.03% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 131.81% year-over-year, with the annual reading at $71438.0 for FY2025, 89.19% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$1.5 million at Theravance Biopharma, down from $6500.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $10.9 million in Q4 2023, with the low at -$11.9 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$103550.0, with a median of -$29250.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes crashed 3647.69% in 2022, then skyrocketed 621.86% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$11.9 million in 2021, then soared by 117.29% to $2.1 million in 2022, then surged by 427.25% to $10.9 million in 2023, then tumbled by 57.75% to $4.6 million in 2024, then tumbled by 132.03% to -$1.5 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$1.5 million, $6500.0, and $50500.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.